Report Detail
North America Narcolepsy Market to 2027 - Regional Analysis and Forecasts By Type (Narcolepsy with Cataplexy, Narcolepsy without Cataplexy, and Secondary Narcolepsy); Product (Central Nervous System (CNS) Stimulants, Sodium Oxybate, and Antidepressants); Distribution Channel (Hospital Pharmacies and Retail Pharmacies) and Country
- RnM3876514 |
- 07 February, 2020 |
- Global |
- 118 Pages |
- The Insight Partners |
- Pharma & Healthcare
North America, the narcolepsy market, is anticipated to reach US$ 2,024.8 Mn in 2027 from US$ 919.6 Mn in 2018. The market is projected to grow with a CAGR of 9.3% from 2019-2027.
The narcolepsy market is expected to grow due to key driving factors such as rising sleep disorders and growing pharmaceutical industry. The market is divided into three countries such as the United States, Canada, and Mexico. The driving for these countries include increase in the demand of rare disease medications from biopharmaceutical and biotechnology companies, presence of key market players and extensive R&D conducted by various academic and research institutes. In addition, extensive research in pharmaceutical and biotechnology companies further expected stimulate the growth of Narcolepsy market in North America.
The North America region is the largest market for the pharmaceutical industry. The countries such as the United States and Canada are leading countries that are the innovators for various innovations in the pharmaceutical industry. The United States has various regulatory bodies that regulate the manufacturing of pharmaceutical products. Regulating bodies such as the US FDA encourages and promotes the development of treatment for rare diseases. Also, increasing incidences are increasing the demand for treatments and better health conditions. Also, the growing population across the North American countries are also leading to an increasing need for the treatments.
In addition, the country is experiencing a rise in the number of start-ups in the pharmaceutical industry in the region. Also, the pharmaceutical industry is also growing due to various strategic developments such as market consolidation, new product development, increasing expansion of the local players to other regions. Moreover, the country spends more on the pharmaceutical industry that enables them to expand their innovations and production capacity. Furthermore, various companies invest in contract manufacturing, which strategically helps companies to expand their production capacity. Also, the countries in the North American region have adopted the use of generic drugs, which is leading to increasing numbers of foreign players to enter the United States and Canadian markets.
The focus on biopharmaceutical and personalized medicines have increased the research and development of the products. The increasing development in the pharmaceutical industry is expected to increase innovations for the medicines that treat narcolepsy.
The narcolepsy market is segmented as type, product and distribution channels. Based on type the market is segmented as narcolepsy with cataplexy, narcolepsy without cataplexy, and secondary narcolepsy. Based on the product the market is categorized as central nervous system (CNS) stimulants, sodium oxybate, and antidepressants. And based on distribution channel the market is classified as hospital pharmacies and retail pharmacies.
North America narcolepsy market is segmented as type, product and distribution channels. Based on type the market is segmented as narcolepsy with cataplexy, narcolepsy without cataplexy, and secondary narcolepsy. Based on the product the market is categorized as central nervous system (CNS) stimulants, sodium oxybate, and antidepressants. And based on distribution channel the market is classified as hospital pharmacies and retail pharmacies.
In 2018, the hospital pharmacies segment held a largest market share of the narcolepsy market, by distribution channel. This segment is expected to dominate the market in 2027 owing to the rising prescription for narcolepsy drugs that are distributed through hospital pharmacies. The segment is also anticipated to witness the fastest growth rate during the forecast period, 2019 to 2027.
Some of the significant primary and secondary sources for Narcolepsy included in the report are American Journal of Medicine, Pharmaceutical Research and Manufacturers Association, Canadian Association for Neuroscience Association, and others.
TABLE OF CONTENTS
1. Introduction
- 1.1 Scope of The Study
- 1.2 The Insight Partners Research Report Guidance
2. North America Narcolepsy Market – Key Takeaways
3. North America Narcolepsy Market – Market Landscape
- 3.1 Overview
- 3.2 Market Segmentation
- 3.2.1 North America Narcolepsy Market – By Type
- 3.2.2 North America Narcolepsy Market – By Product
- 3.2.3 North America Narcolepsy Market – By Distribution Channel
- 3.2.4 North America Narcolepsy Market – By Country
- 3.3 Pest Analysis
4. North America Narcolepsy Market-Key Dynamics
- 4.1 Key Market Drivers
- 4.1.1 Rising Sleep Disorders
- 4.1.2 Growing Pharmaceutical Industry
- 4.2 Key Market Restraints
- 4.2.1 No Cure Treatment for Narcolepsy
- 4.3 Key Market Opportunity
- 4.3.1 Awareness Programs for Narcolepsy
- 4.4 Future Trend
- 4.4.1 Developments in Pharmaceutical Sector to Treat Narcolepsy
- 4.5 Impact Analysis Of Drivers and Restraints
5. Narcolepsy Market – Regional Analysis
- 5.1 North America Narcolepsy Market Revenue Forecasts and Analysis
- 5.2 Performance Of Key Players
- 5.2.1 Jazz Pharmaceuticals plc
- 5.2.2 Teva Pharmaceutical Industries Ltd.
6. Narcolepsy Market Analysis and Forecasts to 2027 – Type
- 6.1 Overview
- 6.2 Type Market Revenue and Forecasts Analysis (US$ Mn)
- 6.3 North America Narcolepsy With Cataplexy Market Revenue and Forecasts To 2027, By Type (Us$ Mn)
- 6.4 Narcolepsy With Cataplexy Market
- 6.4.1 Overview
- 6.4.2 Narcolepsy With Cataplexy Market Revenue and Forecast to 2027 (US$ Mn)
- 6.5 Narcolepsy Without Cataplexy Market
- 6.5.1 Overview
- 6.5.2 Narcolepsy Without Cataplexy Market Revenue and Forecast to 2027 (US$ Mn)
- 6.6 Secondary Narcolepsy Market
- 6.6.1 Overview
- 6.6.2 Secondary Narcolepsy Market Revenue and Forecast to 2027 (US$ Mn)
7. Narcolepsy Market Analysis and Forecasts to 2027 – Product
- 7.1 Overview
- 7.2 Product Market Revenue and Forecasts Analysis (US$ Mn)
- 7.3 North America Narcolespy Market Revenue and Forecasts To 2027, By Product (US$ Mn)
- 7.4 Central Nervous System Stimulants Market
- 7.4.1 Overview
- 7.4.2 Central Nervous System Stimulants Market Revenue and Forecast to 2027 (US$ Mn)
- 7.5 Sodium Oxybate Market
- 7.5.1 Overview
- 7.5.2 Sodium Oxybate Market Revenue and Forecast to 2027 (US$ Mn)
- 7.6 Antidepressants Market
- 7.6.1 Overview
- 7.6.2 Antidepressants Market Revenue and Forecast to 2027 (US$ Mn)
8. Narcolepsy Market Analysis and Forecasts to 2027 – Distribution Channel
- 8.1 Overview
- 8.2 Distribution Channel Market Revenue and Forecasts Analysis (US$ Mn)
- 8.3 North America Narcolespy Market Revenue and Forecasts To 2027, By End User (US$ Mn)
- 8.4 Hospital Pharmacies Market
- 8.4.1 Overview
- 8.4.2 Hospital Pharmacies Market Revenue and Forecast to 2027 (US$ Mn)
- 8.5 Retail Pharmacies Market
- 8.5.1 Overview
- 8.5.2 Retail Pharmacies Market Revenue and Forecast to 2027 (US$ Mn)
9. Narcolepsy Market Revenue And Forecasts To 2027 – Geographical Analysis
- 9.1 North America Narcolepsy Market
- 9.1.1 Overview
- 9.1.2 North America Narcolepsy Market Revenue and Forecasts to 2027 (US$ Mn)
- 9.1.3 North America Narcolepsy Market Revenue and Forecasts to 2027, By Type (US$ Mn)
- 9.1.4 North America Narcolepsy Market Revenue and Forecasts to 2027, By Product (US$ Mn)
- 9.1.5 North America Narcolepsy Market Revenue and Forecasts to 2027, By Distribution Channel (US$ Mn)
- 9.1.6 North America Narcolepsy Market Revenue and Forecasts to 2027, By Country (%)
- 9.1.7 US Narcolepsy Market Revenue and Forecasts to 2027 (US$ Mn)
- 9.1.8 US Narcolepsy Market Revenue and Forecasts to 2027 (US$ Mn)
- 9.1.8.1 US Narcolepsy Market Revenue and Forecasts to 2027, By Type (US$ Mn)
- 9.1.8.2 US Narcolepsy Market Revenue and Forecasts to 2027, By Product (US$ Mn)
- 9.1.8.3 US Narcolepsy Market Revenue and Forecasts to 2027, By Distribution Channel (US$ Mn)
- 9.1.9 Canada Narcolepsy Market Revenue and Forecasts to 2027 (US$ Mn)
- 9.1.10 Canada Narcolepsy Market Revenue and Forecasts to 2027 (US$ Mn)
- 9.1.10.1 Canada Narcolepsy Market Revenue and Forecasts to 2027, By Type (US$ Mn)
- 9.1.10.2 Canada Narcolepsy Market Revenue and Forecasts to 2027, By Product (US$ Mn)
- 9.1.10.3 Canada Narcolepsy Market Revenue and Forecasts to 2027, By Distribution Channel (US$ Mn)
- 9.1.11 Mexico Narcolepsy Market Revenue and Forecasts to 2027 (US$ Mn)
- 9.1.12 Mexico Narcolepsy Market Revenue and Forecasts to 2027 (US$ Mn)
- 9.1.12.1 Mexico Narcolepsy Market Revenue and Forecasts to 2027, By Type (US$ Mn)
- 9.1.12.2 Mexico Narcolepsy Market Revenue and Forecasts to 2027, By Product (US$ Mn)
- 9.1.12.3 Mexico Narcolepsy Market Revenue and Forecasts to 2027, By Distribution Channel (US$ Mn)
10. Narcolepsy Market – Industry Landscape
- 10.1 Overview
- 10.2 Comparative Company Analysis
- 10.3 Growth Strategies Done By The Companies In The Market, (%)
- 10.4 Organic Developments
- 10.4.1 Overview
- 10.5 Inorganic Developments
- 10.5.1 Overview
11. Narcolepsy Market –Key Company Profiles
- 11.1 Teva Pharmaceutical Industries Ltd.
- 11.1.1 Key Facts
- 11.1.2 Business Description
- 11.1.3 Financial Overview
- 11.1.4 Product Portfolio
- 11.1.5 SWOT Analysis
- 11.1.6 Key Developments
- 11.2 Jazz Pharmaceuticals Plc
- 11.2.1 Key Facts
- 11.2.2 Business Description
- 11.2.3 Financial Overview
- 11.2.4 Product Portfolio
- 11.2.5 SWOT Analysis
- 11.2.6 Key Developments
- 11.3 Arena Pharmaceuticals, Inc.
- 11.3.1 Key Facts
- 11.3.2 Business Description
- 11.3.3 Financial Overview
- 11.3.4 Product Portfolio
- 11.3.5 SWOT Analysis
- 11.3.6 Key Developments
- 11.4 Graymark Healthcare, Inc.
- 11.4.1 Key Facts
- 11.4.2 Business Description
- 11.4.3 Financial Information
- 11.4.4 Product Portfolio
- 11.4.5 SWOT Analysis
- 11.4.6 Key Developments
- 11.5 Novartis AG
- 11.5.1 Key Facts
- 11.5.2 Business Description
- 11.5.3 Financial Information
- 11.5.4 Product Portfolio
- 11.5.5 SWOT Analysis
- 11.5.6 Key Developments
- 11.6 Takeda Pharmaceutical Company Limited
- 11.6.1 Key Facts
- 11.6.2 Business Description
- 11.6.3 Financial Information
- 11.6.4 Product Pipeline
- 11.6.5 SWOT Analysis
- 11.6.6 Key Developments
- 11.7 Mylan N.V.
- 11.7.1 Key Facts
- 11.7.2 Business Description
- 11.7.3 Financial Overview
- 11.7.4 Product Portfolio
- 11.7.5 SWOT Analysis
- 11.7.6 Key Developments
- 11.8 Bioprojet
- 11.8.1 Key Facts
- 11.8.2 Business Description
- 11.8.3 Financial Overview
- 11.8.4 Product Portfolio
- 11.8.5 SWOT Analysis
- 11.8.6 Key Developments
- 11.9 Shionogi & Co., Ltd.
- 11.9.1 Key Facts
- 11.9.2 Business Description
- 11.9.3 Financial Overview
- 11.9.4 Product Portfolio
- 11.9.5 Product Pipeline
- 11.9.6 SWOT Analysis
- 11.9.7 Key Developments
- 11.10 Ligand Pharmaceuticals, Inc.
- 11.10.1 Key Facts
- 11.10.2 Business Description
- 11.10.3 Financial Overview
- 11.10.4 Product Portfolio
- 11.10.5 Product Pipeline
- 11.10.6 SWOT Analysis
- 11.10.7 Key Developments
12. Appendix
- 12.1 About The Insight Partners
- 12.2 Glossary Of Terms
- 12.3 Methodology
- 12.3.1 Coverage
- 12.3.2 Secondary Research
Summary:
Get latest Market Research Reports on North America Narcolepsy . Industry analysis & Market Report on North America Narcolepsy is a syndicated market report, published as North America Narcolepsy Market to 2027 - Regional Analysis and Forecasts By Type (Narcolepsy with Cataplexy, Narcolepsy without Cataplexy, and Secondary Narcolepsy); Product (Central Nervous System (CNS) Stimulants, Sodium Oxybate, and Antidepressants); Distribution Channel (Hospital Pharmacies and Retail Pharmacies) and Country. It is complete Research Study and Industry Analysis of North America Narcolepsy market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
